IPSEN PHARMA S.A.S

DIZAFET

Pharmaceutical preparations for use in the prevention, treatment, and cure of oncological, endocrine, neurological, hematological, gastroenterological, and urological conditions and diseases and for the prevention, treatment, and cure of cardiovascular and cognitive disorders;The word(s) Dizafet has no meaning in a foreign language.;

EMARQIA

Pharmaceutical preparations for use in the prevention, treatment, and cure of oncological, endocrine, neurological, gastroenterological, and urological conditions and diseases and for the prevention, treatment, and cure of cardiovascular and cognitive disorders;

EXGILIA

Pharmaceutical products in the field of oncology;

EXGILIA

Pharmaceutical products in the field of oncology;

GANESVA

Pharmaceutical preparations for use in oncology, endocrinology, neurology, hematology, gastroenterology, urology and for cardiovascular and cognitive disorders;

INNOVATORS IN BC

Training services in the field of of bladder cancer; Publication of books; Publication of electronic magazines; Publication of printed matter, namely, calendars of events; Publication of printed matter; Publication of printed matter, namely, magazines, newspapers, and brochures; Electronic publishing services, namely, publication of text and graphic works of others on CD and DVD featuring information in the field of bladder cancer; Multimedia publishing of software; Publication of books, electronic magazines, printed calendars of events, printed magazines, newspapers, and brochures, all in the medical and pharmaceutical fields; Electronic publishing services, namely, publication of text and graphic works of others on CD and DVD featuring information in the fields of medicine and pharmaceuticals; Education, teaching and training in the medical and pharmaceutical fields, namely, providing classes, seminars, workshops in the aforementioned fields; Organizing and conducting colloquiums, conferences, conventions, seminars and symposiums in the medical and pharmaceutical fields for non-business and non-commercial purposes;The mark consists of the stylized wording INNOVATORS IN BC; the letters A and V in INNOVATORS are more heavily stylized than the remainder of the lettering in the mark; the aforementioned V has a dark blue left-hand portion and a purple-right-hand portion; the aforementioned A has a light blue left-hand portion and a dark blue right-hand portion; all other lettering in the mark appears in the color dark blue.;Providing discussion forums on the Internet, namely, providing on-line forums for transmission of messages among computer users in the field of bladder cancer; Electronic bulletin board services; Providing an on-line forum for discussion of issues in the field of bladder cancer; Provision of access to online databases; Transmission of data via global computer or electronic networks;The color(s) light blue, dark blue and purple is/are claimed as a feature of the mark.;Provision of medical information on cancer of the bladder, including information provided via an Internet Website;BC;

IQTARA

Pharmaceutical preparations for use in the prevention, treatment, and cure of oncological, endocrine, neurological, hematological, gastroenterological, and urological conditions and diseases and for the prevention, treatment, and cure of cardiovascular and cognitive disorders;The wording IQTARA has no meaning in a foreign language.;

ITAZDA

Pharmaceutical preparations for use in the prevention, treatment, and cure of oncological, endocrine, neurological, hematological, gastroenterological, and urological conditions and diseases and for the prevention, treatment, and cure of cardiovascular and cognitive disorders;The wording ITAZDA has no meaning in a foreign language.;

ITERSTA

Pharmaceutical products, namely, pharmaceutical preparations for use in oncology, endocrinology, neurology, hematology, gastroenterology, urology and for cardiovascular and cognitive disorders;

ITESQA

Pharmaceutical preparations for use in the prevention, treatment, and cure of oncological, endocrine, neurological, gastroenterological, and urological conditions and diseases and for the prevention, treatment, and cure of cardiovascular, cognitive and gastrointestinal diseases and disorders;

IZEOXA

Pharmaceutical preparations for the treatment and prevention of endocrine diseases and disorders, gastroenterological diseases and disorders, oncological diseases and disorders, urological diseases and disorders, central nervous system diseases and disorders, and neurological diseases and disorders;

LESOLIA

Pharmaceutical preparations for use in the prevention, treatment, and cure of oncological, endocrine, neurological, hematological, gastroenterological, and urological conditions and diseases and for the prevention, treatment, and cure of cardiovascular and cognitive disorders;The word(s) Lesolia has no meaning in a foreign language.;

MYENEV

Pharmaceutical products, namely, pharmaceutical preparations for use in oncology, endocrinology, neurology, hematology, gastroenterology, urology and for cardiovascular and cognitive disorders;

ONTELRIQ

Pharmaceutical preparations for use in oncology, endocrinology, neurology, hematology, gastroenterology, uroloty and for cardivascular and cognitive disorders;

ONTELRIQ

Pharmaceutical products;

QAZIREQ

Pharmaceutical preparation for use in the prevention, treatment, and cure of oncological, endocrine, neurological, gastroenterological, and urological conditions and diseases and for the prevention, treatment and cure of cardiovascular and cognitive disorders;

QETYPRA

Pharmaceutical preparations for use in the prevention, treatment and cure of oncological, endocrinological, neurological, gastroenterological, gastrointestinal and urological conditions and diseases and for the prevention, treatment and cure of cardiovascular and cognitive disorders;

QETYPRA

Pharmaceutical products;

RETASQI

Pharmaceutical preparations for use in oncology, endocrinology, neurology, hematology, gastroenterology, urology and for cardiovascular and cognitive disorders;

SANREEVI

Pharmaceutical products, namely, pharmaceutical preparations for use in oncology, endocrinology, neurology, hematology, gastroenterology, urology and for cardiovascular and cognitive disorders;

SATOTERRA

Conducting clinical trials for others; conducting clinical trials for pharmaceutical products for others; providing information relating to medical and scientific research in the field of pharmaceutical products and clinical trials; testing of pharmaceuticals;

SMECTA

Pharmaceutical products, namely, preparations for the treatment of gastrointestinal diseases;

TALQAZI

Pharmaceutical preparations for use in the prevention, treatment, and cure of oncological, endocrine, neurological, hematological, gastroenterological, and urological conditions and diseases and for the prevention, treatment, and cure of cardiovascular and cognitive disorders;The wording TALQAZI has no meaning in a foreign language.;

TALQAZI

pharmaceutical preparations for use in the prevention, treatment, and cure of oncological, endocrine, neurological, hematological, gastroenterological, and urological conditions and diseases and for the prevention, treatment, and cure of cardiovascular and cognitive disorders;

TARMIQRA

Pharmaceutical preparations for use in the prevention, treatment, and cure of oncological, endocrine, neurological, hematological, gastroenterological, and urological conditions and diseases and for the prevention, treatment, and cure of cardiovascular and cognitive disorders;The wording TARMIQRA has no meaning in a foreign language.;

TASQIAN

Pharmaceutical preparations for use in oncology, endocrinology, neurology, hematology, gastroenterology, urology and for cardiovascular and cognitive disorders;

TASQIVO

Pharmaceutical preparations for use in oncology, endocrinology, neurology, hematology, gastroenterology, urology and for cardiovascular and cognitive disorders;

XANGIUS

Pharmaceutical preparations for use in oncology, endocrinology, neurology, hematology, gastroenterology, urology and for cardiovascular and cognitive disorders;

XUMITASQ

Pharmaceutical preparations for use in oncology, endocrinology, neurology, hematology, gastroenterology, urology and for cardiovascular and cognitive disorders;

YNEXSTA

Pharmaceutical preparations for use in oncology, endocrinology, neurology, hematology, gastroenterology, urology and for cardiovascular and cognitive disorders;

YNEXSTA

Pharmaceutical products;

YNOXSET

Pharmaceutical preparations for the treatment and prevention of endocrine diseases and disorders, gastroenterological diseases and disorders, oncological diseases and disorders, urological diseases and disorders, central nervous system diseases and disorders, and neurological diseases and disorders;

ZELUTIS

Pharmaceutical preparations for use in the prevention, treatment, and cure of oncological, endocrine, neurological, hematological, gastroenterological, and urological conditions and diseases and for the prevention, treatment, and cure of cardiovascular and cognitive disorders;The word(s) Zelutis has no meaning in a foreign language.;